What Marea Therapeutics does

Marea Therapeutics, Inc. is a clinical-stage biotechnology company headquartered at 131 Oyster Point Boulevard in South San Francisco, California, developing first-in-class therapies for cardioendocrine diseases. The company was founded with backing from Third Rock Ventures (which co-developed the concept via Ethan Weiss's entrepreneur-in-residence engagement) and is led by CEO Josh Lehrer, M.D., former CEO of Graphite Bio and Chief Medical Officer of Global Blood Therapeutics. Marea's discovery engine is built on large-scale human genetic data combined with adipocyte biology to identify genetically validated targets, with the goal of treating underlying disease biology rather than symptoms. Its lead programs are MAR001, a first-in-class anti-ANGPTL4 monoclonal antibody in Phase 2b development for severe hypertriglyceridemia (sHTG) and atherosclerotic cardiovascular disease (ASCVD); MAR002, a half-life-extended allosteric growth hormone receptor antagonist monoclonal antibody for acromegaly, which produced positive Phase 1 data in January 2026 demonstrating 52% peak IGF-1 suppression and durability supportive of biweekly to monthly dosing; and MAR003, an undisclosed ASCVD target in discovery. The company is also advancing a half-life-extended MAR001 (MAR001-HLE) toward an IND filing in 2026 and an adipose-targeted ANGPTL4 siRNA preclinical program.

Marea's business model is presently pre-revenue. As a clinical-stage biotech, it generates no product sales and funds operations through venture capital. The company filed an SEC Form D in June 2024 covering approximately $190 million in aggregate securities, including a $190 million Series A financing (with a concurrent ~$65 million Third Rock Ventures tranche) led by Forbion, Perceptive Advisors, Sofinnova Investments, and venBio Partners, alongside Alpha Wave, Omega Funds, Surveyor, and Third Rock Ventures. Future revenue mechanics are expected to derive from pharmaceutical commercialization upon regulatory approval, supplemented by potential out-licensing or partnership transactions, with traditional pharmaceutical distribution and direct sales channels planned. Marea's go-to-market strategy today is enterprise field sales in nature — building scientific credibility, clinical data assets, and pharmaceutical partnerships through presentations at medical conferences (e.g., ENDO 2026) and press releases, ahead of any commercial launch. The company operates a wholly-owned Australian subsidiary (Marea Therapeutics Pty Ltd) coordinating Australian clinical activities, and serves an eventual addressable market of patients with cardioendocrine diseases including severe hypertriglyceridemia, ASCVD, and acromegaly (~30,000+ U.S. acromegaly patients).

Name

Marea Therapeutics

Legal name

Marea Therapeutics, Inc.

Website

https://www.mareatx.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Marea Therapeutics is a clinical-stage biotechnology company developing first-in-class monoclonal antibody and siRNA therapies for cardioendocrine diseases, including severe hypertriglyceridemia, ASCVD, and acromegaly, serving patients with limited effective treatment options.

Ownership category

akta.pro rank

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Development and Commercialization: As a clinical-stage biotechnology company, Marea Therapeutics is developing novel therapeutics with the goal of commercializing pharmaceutical products for cardioendocrine diseases. The company has not yet generated revenue from product sales. MAR001 is in Phase 2b for severe hypertriglyceridemia and ASCVD, and MAR002 is advancing toward Phase 2/3 for acromegaly.
2. Securities Offering / Funding: The company raised approximately $160 million through a Form D SEC filing for exempt securities offering, with around $65 million already sold as of June 2024.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Marea Therapeutics is a clinical-stage biotechnology company developing a pipeline of first-in-class monoclonal antibody and siRNA therapeutics that target genetically validated drivers of cardioendocrine diseases, including severe hypertriglyceridemia, atherosclerotic cardiovascular disease, and acromegaly. Its lead candidates are MAR001 (an anti-ANGPTL4 monoclonal antibody in Phase 2b), MAR002 (a half-life-extended allosteric growth hormone receptor antagonist antibody for acromegaly), and MAR003 (an undisclosed ASCVD program in discovery).

Product overview

Marea Therapeutics is a clinical-stage biotechnology company developing a pipeline of first-in-class therapies targeting cardioendocrine diseases. The company's core portfolio includes three product candidates: MAR001 (ANGPTL4 inhibitor, Phase 2) for severe hypertriglyceridemia and ASCVD; MAR002 (GHR antagonist, IND-Enabling) for acromegaly; and MAR003 (undisclosed target, discovery stage) for ASCVD. The company is also advancing MAR001-HLE, a half-life-extended formulation of MAR001 designed for monthly dosing, and an ANGPTL4 siRNA preclinical program targeting adipose tissue.

Differentiator

Problem solved

Functional benefit

Products and services

• MAR001 A first-in-class monoclonal antibody targeting ANGPTL4 (angiopoietin-like 4 protein) designed to block the activity of this genetically validated driver of remnant cholesterol and atherosclerotic cardiovascular disease risk, leading to augmented hydrolysis of triglyceride-rich lipoproteins and reductions in triglycerides and remnant cholesterol. Currently in Phase 2b for severe hypertriglyceridemia and ASCVD.
• MAR002 A potent and selective half-life-extended, allosteric, human monoclonal growth hormone receptor antagonist (GHRA) antibody being developed for the treatment of acromegaly. Designed for infrequent subcutaneous dose administration, potentially enabling dosing as infrequently as once every two weeks compared to daily injections required by the current standard of care.
• MAR003 An undisclosed discovery-stage program targeting a genetically validated driver of atherosclerotic cardiovascular disease (ASCVD).
• MAR001-HLE A half-life-extended version of MAR001 incorporating Fc modifications designed to improve pharmacokinetics, enable monthly low-volume subcutaneous dosing, and significantly reduce cost of goods. Advancing toward Phase 3 readiness with IND filing anticipated in 2026.
• ANGPTL4 siRNA Program A preclinical small interfering RNA (siRNA) program targeting ANGPTL4 with a differentiated, adipose-tissue-focused approach, intended to complement Marea's monoclonal antibody pipeline with a next-generation modality.

Quantifiable outcome

• MAR002 achieved 52% peak IGF-1 suppression with greater than 45% suppression lasting 43 days (vs. 48% peak and greater than 45% lasting only 5 days for current standard of care)
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators1 record

Recent moves7 records

Expansion highlights5 records

Direct peers

• Crinetics Pharmaceuticals: Crinetics is a clinical-stage endocrine-focused biotech whose lead asset paltusotine (oral nonpeptide somatostatin agonist) is in Phase 3 for acromegaly — making it the most direct head-to-head competitor to MAR002 in the same indication with a similar patient population.
• Camurus: Camurus is developing CAM2029, a subcutaneous weekly octreotide formulation in Phase 3 for acromegaly, directly competing with MAR002 on dosing-convenience differentiation within the same rare endocrine indication.
• Madrigal Pharmaceuticals: Madrigal developed resmetirom (Rezdiffra) for MASH with cardiovascular comorbidities, and is the closest peer in the cardioendocrine/metabolic liver-heart intersection that Marea also targets with ANGPTL4 and GHR programs.
• NewAmsterdam Pharma: NewAmsterdam is a late-stage cardiometabolic biotech developing obicetrapib (CETP inhibitor) for dyslipidemia and ASCVD risk reduction — directly comparable to Marea's MAR001 program in mechanism, indication, and stage of cardiovascular lipid management development.

Broad incumbents

• Alnylam Pharmaceuticals: Alnylam is the established leader in siRNA therapeutics (Onpattro, Givlaari, Oxlumo, Leqvio via Novartis partnership) and is the most relevant platform peer to Marea's emerging adipose-targeted ANGPTL4 siRNA program, defining the competitive and partnering landscape for RNAi-based cardiometabolic medicines.
• Ionis Pharmaceuticals: Ionis is a leader in RNA-targeted therapeutics (antisense oligonucleotides) with multiple cardiometabolic programs (e.g., olezarsen for familial chylomicronemia, plozasiran via Arrowhead collaboration), making it a direct platform and indication peer to both MAR001 and the siRNA program.
• BridgeBio Pharma: BridgeBio develops genetic-disease medicines including cardiovascular programs (e.g., acoramidis for transthyretin amyloid cardiomyopathy, approved as Attruby). Its genetically validated target approach parallels Marea's discovery strategy and its late-stage cardiovascular experience makes it a relevant comparator.

Emerging players

• Verve Therapeutics: Verve is a clinical-stage genetic medicines company developing in vivo gene editing for cardiovascular disease (VERVE-101, VERVE-102 for PCSK9). It shares Marea's genetically validated cardiovascular target strategy but uses a different modality (base editing vs. monoclonal antibody/siRNA).
• Lexicon Pharmaceuticals: Lexicon is developing sotagliflozin (SGLT1/2 inhibitor) for heart failure and other cardioendocrine indications. While smaller and at a different stage, its focus on cardioendocrine mechanisms and cardiovascular outcomes development makes it a relevant emerging peer.
• Soleno Therapeutics: Soleno develops diazoxide choline extended-release (DCCR) for Prader-Willi syndrome and has explored related rare endocrine and metabolic indications. Its late-stage rare endocrine focus and small-cap clinical biotech profile make it a comparable peer for MAR002's rare-disease positioning strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/Marea_tx
• LinkedInlinkedin.com/company/marea-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marea Therapeutics